Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LRMR Stock Forecast 2025-2026
$1.87
Current Price
$114.61M
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LRMR Price Targets
+2,039.0%
To High Target of $40.00
+835.8%
To Median Target of $17.50
+434.8%
To Low Target of $10.00
LRMR Price Momentum
-11.8%
1 Week Change
+1.6%
1 Month Change
-74.8%
1 Year Change
-51.7%
Year-to-Date Change
-83.3%
From 52W High of $11.20
+16.1%
From 52W Low of $1.61
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Larimar (LRMR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LRMR and similar high-potential opportunities.
Latest LRMR Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, LRMR has a bullish consensus with a median price target of $17.50 (ranging from $10.00 to $40.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $1.87, the median forecast implies a 835.8% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 434.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LRMR Analyst Ratings
12
Buy
0
Hold
0
Sell
LRMR Price Target Range
Low
$10.00
Average
$17.50
High
$40.00
Current: $1.87
Latest LRMR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LRMR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $26.00 |
| Mar 25, 2025 | Baird | Joel Beatty | Outperform | Maintains | $10.00 |
| Mar 25, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $16.00 |
| Jan 29, 2025 | Truist Securities | Joon Lee | Buy | Initiates | $18.00 |
| Jan 24, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Oct 16, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Initiates | $26.00 |
| Oct 3, 2024 | Wedbush | Laura Chico | Outperform | Initiates | $22.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Edward White | Buy | Initiates | $15.00 |
| Sep 12, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $14.00 |
| Sep 4, 2024 | Baird | Joel Beatty | Outperform | Initiates | $16.00 |
| May 31, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
| May 22, 2024 | Citigroup | Samantha Semenkow | Buy | Maintains | $14.00 |
| May 21, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
| Apr 3, 2024 | Leerink Partners | Joori Park | Outperform | Initiates | $25.00 |
| Mar 15, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
| Mar 12, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $25.00 |
Larimar Therapeutics Inc. (LRMR) Competitors
The following stocks are similar to Larimar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Larimar Therapeutics Inc. (LRMR) Financial Data
Larimar Therapeutics Inc. has a market capitalization of $114.61M with a P/E ratio of -1.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -50.8%.
Valuation Metrics
Market Cap
$114.61M
Enterprise Value
$-32,607,702
P/E Ratio
-1.4x
PEG Ratio
-1.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+131.6%
Current Ratio
7.5x
Debt/Equity
3.4x
ROE
-50.8%
ROA
-31.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Larimar Therapeutics Inc. (LRMR) Business Model
About Larimar Therapeutics Inc.
What They Do
Develops treatments for complex rare diseases.
Business Model
Larimar Therapeutics operates as a biotechnology company focused on developing innovative therapies for rare diseases, particularly mitochondrial disorders. The company generates revenue through the development and commercialization of its product candidates, which aim to address significant unmet medical needs in the healthcare sector.
Additional Information
The company's key research area includes Friedrich's ataxia, a condition with limited treatment options. Larimar Therapeutics utilizes advanced scientific methods and maintains a patient-centric approach to optimize treatment efficacy through ongoing clinical trials and collaborations. This focus on niche therapeutic areas aligns with the broader trend towards personalized medicine in the biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Dr. Carole S. Ben-Maimon M.D.
Country
United States
IPO Year
2014
Website
larimartx.comLarimar Therapeutics Inc. (LRMR) Latest News & Analysis
Latest News
Quick Summary
Larimar Therapeutics is considering a BLA for accelerated approval by late 2025, with a Phase 3 study set for mid-2025. As of March 31, 2025, it has $157.5M in cash, extending its runway into Q2 2026.
Why It Matters
Larimar Therapeutics' potential accelerated approval pathway and strong cash position signal growth opportunities, making it a key player in biotech for investors seeking promising rare disease treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar Therapeutics (Nasdaq: LRMR) reported its Q4 and full year 2024 financial results, focusing on treatments for complex rare diseases.
Why It Matters
Larimar's financial results can impact stock performance and investor sentiment, signaling progress or challenges in its drug development for rare diseases, influencing future funding and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar Therapeutics (Nasdaq: LRMR) will present and hold 1x1 investor meetings at the Leerink Partners Global Healthcare Conference in Miami Beach from March 10-12, 2025.
Why It Matters
Larimar's participation in a major healthcare conference signals potential investor interest and insights into its development pipeline, which could influence stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar Therapeutics has begun dosing adolescents aged 12-17 in a pediatric study for Friedreich's ataxia, advancing its clinical development efforts in rare diseases.
Why It Matters
Larimar's initiation of a pediatric study for Friedreich's ataxia signals progress in drug development, potentially increasing its market value and attractiveness to investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Larimar Therapeutics reported positive Phase 2 data for nomlabofusp in Friedreich's Ataxia, showing a 15%-30% increase in FXN protein levels. The market is projected at $2.06 billion by 2030, with more data expected in mid-2025.
Why It Matters
Positive phase 2 data for nomlabofusp enhances Larimar's growth potential in the $2.06 billion Friedreich's Ataxia market, signaling future revenue opportunities and increased investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Larimar Therapeutics released initial data from an ongoing study on nomlabofusp for Friedreich's Ataxia, evaluating 25 mg daily injections, either self-administered or by a caregiver.
Why It Matters
Initial data from Larimar's study on nomlabofusp could indicate the drug's efficacy for Friedreich's Ataxia, impacting future stock performance and market sentiment in biotech.
Source: Benzinga
Market Sentiment:
Neutral
Frequently Asked Questions About LRMR Stock
What is Larimar Therapeutics Inc.'s (LRMR) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Larimar Therapeutics Inc. (LRMR) has a median price target of $17.50. The highest price target is $40.00 and the lowest is $10.00.
Is LRMR stock a good investment in 2025?
According to current analyst ratings, LRMR has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LRMR stock?
Wall Street analysts predict LRMR stock could reach $17.50 in the next 12 months. This represents a 835.8% increase from the current price of $1.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Larimar Therapeutics Inc.'s business model?
Larimar Therapeutics operates as a biotechnology company focused on developing innovative therapies for rare diseases, particularly mitochondrial disorders. The company generates revenue through the development and commercialization of its product candidates, which aim to address significant unmet medical needs in the healthcare sector.
What is the highest forecasted price for LRMR Larimar Therapeutics Inc.?
The highest price target for LRMR is $40.00 from at , which represents a 2,039.0% increase from the current price of $1.87.
What is the lowest forecasted price for LRMR Larimar Therapeutics Inc.?
The lowest price target for LRMR is $10.00 from Joel Beatty at Baird, which represents a 434.8% increase from the current price of $1.87.
What is the overall LRMR consensus from analysts for Larimar Therapeutics Inc.?
The overall analyst consensus for LRMR is bullish. Out of 12 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.50.
How accurate are LRMR stock price projections?
Stock price projections, including those for Larimar Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 8:31 AM UTC